Author: Fiona Craig

Sure Ventures PLC (LSE:SURE) reported a modest increase in Net Asset Value during the third quarter of 2025, largely driven by favourable foreign exchange movements. The update reflects continued progress across the group’s investment portfolio alongside further capital deployment into its core venture funds.

During the quarter, the company increased its exposure to both the Sure Valley Ventures Fund and the Sure Valley Ventures Enterprise Capital Fund. Several portfolio companies delivered notable operational advances, including Zenos Technology, WIA Technologies, and CameraMatics, underscoring the strength of Sure Ventures’ focus on early-stage, high-growth technology businesses.

These developments reinforce the group’s strategic emphasis on emerging technologies, particularly within the software and innovation space. Ongoing portfolio progress highlights the potential for long-term value creation as investee companies continue to scale and commercialise their solutions.

From an investment perspective, Sure Ventures’ underlying valuation and solid financial position contribute positively to its overall profile. Its focus on artificial intelligence and broader technology themes, alongside a track record of successful portfolio exits, supports a constructive long-term outlook. However, bearish technical signals point to near-term caution, while effective cash flow management remains an area of attention.

More about Sure Ventures PLC

Sure Ventures PLC is a London-listed venture capital company investing in early-stage software businesses operating in high-growth technology sectors. Its investment focus includes Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), and the Internet of Things (IoT), targeting innovative companies with strong scalability potential.

Jersey Electricity plc (LSE:JEL) reported a solid set of results for the year ended 30 September 2025, with revenue rising 8% to £146.2 million, supported by continued growth in its Energy division and higher customer demand. While profit before tax eased slightly, largely due to property revaluation movements and increased pension-related costs, the group’s underlying financial position remained robust.

The Board proposed a 5% increase in the dividend, reflecting confidence in cash generation and balance sheet strength despite the impact of non-operational items on reported profits. Cost discipline and steady top-line growth helped underpin earnings resilience during the period.

Strategically, Jersey Electricity continued to advance key investment programmes aimed at strengthening supply security and accelerating the shift towards sustainable energy. Ongoing initiatives include investment in renewable energy infrastructure, support for electric heating, and the expansion of electric vehicle adoption across the island. These projects align with Jersey’s long-term objective of achieving net zero emissions and reinforce the company’s role in the local energy transition.

From a market perspective, the company’s stable financial performance and appealing valuation metrics underpin its overall investment profile. Consistent revenue growth, prudent cost management, and a dependable dividend yield remain positives, while technical indicators suggest a broadly neutral share price trend with no strong directional signals.

More about Jersey Electricity

Jersey Electricity is an energy company focused primarily on the generation, distribution, and supply of electricity in Jersey. The group plays a central role in the transition to electric heating and transport and is committed to supporting the island’s move towards a more sustainable, reliable, and low-carbon energy system.

AstraZeneca plc (LSE:AZN) has received European Union approval for a new subcutaneous, self-administered version of Saphnelo to treat systemic lupus erythematosus (SLE). The medicine will be available as a pre-filled pen, giving patients greater flexibility and convenience compared with hospital-based administration.

The regulatory decision was supported by positive data from the Phase III TULIP-SC clinical trial, which showed meaningful reductions in disease activity among patients using the subcutaneous formulation. The option for self-administration is expected to broaden access to treatment, support patient choice, and potentially improve adherence and outcomes in this chronic autoimmune condition.

From a broader perspective, the approval adds to AstraZeneca’s growing portfolio of innovative therapies and reflects continued execution on its product development strategy. Strong recent financial performance and a constructive earnings update underpin confidence in the group’s outlook. That said, elevated valuation levels and only moderate technical signals slightly moderate expectations in the near term.

Overall, the expanded label for Saphnelo strengthens AstraZeneca’s position in immunology while reinforcing its focus on delivering patient-centric treatment options through innovation.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. It focuses on the discovery, development, and commercialisation of prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company operates in more than 125 countries and is committed to addressing unmet medical needs through innovative therapies.

Intuitive Investments Group plc (LSE:IIG) released its financial results for the year ended 30 September 2025, underscoring a clear strategic emphasis on Hui10, which now accounts for more than 99% of the group’s investment portfolio. The results highlight Hui10’s strong operational momentum, with notable growth in both connected lottery outlets and registered user numbers.

During the year, Hui10 expanded its footprint across four provinces in China, reflecting steady execution of its regional growth strategy. The business also secured strategic partnerships with well-known commercial brands and state-owned organisations, strengthening its market position and enhancing credibility within the highly regulated lottery sector.

Looking ahead, Hui10 is targeting further expansion of its lottery shop network while progressing towards a paperless lottery model. This transition has the potential to materially reshape the operating model, improve efficiency, and unlock new revenue opportunities, which could deliver long-term benefits for both the business and its shareholders.

From a financial standpoint, Intuitive Investments Group continues to face material headwinds. Declining revenues and negative cash flows present ongoing risks, while weak technical signals and valuation concerns continue to weigh on investor sentiment. Nonetheless, recent corporate developments linked to Hui10’s expansion strategy provide potential upside if growth plans are executed successfully.

More about Intuitive Investments Group plc

Intuitive Investments Group plc is an investment company that offers shareholders exposure to high-growth and emerging businesses across the UK, Europe, the United States, and the Asia-Pacific region. The group focuses on long-term capital appreciation, drawing on the Board’s investment experience. A substantial portion of its portfolio is invested in Hui10, a technology-driven business at the forefront of the digital transformation of China’s lottery market.

SThree plc (LSE:STEM) posted full-year FY25 results broadly in line with expectations, despite a 12% year-on-year drop in net fees amid tough market conditions. The group completed its Technology Improvement Programme across all regions during the year, strengthening operational efficiency and laying the groundwork for more scalable growth.

Operationally, the successful rollout of the Technology Improvement Programme is a key milestone, enabling improved productivity and more streamlined processes across SThree’s global platform. The US business returned to growth during the period, helping to offset weaker performance in other geographies and demonstrating resilience in one of the group’s most important markets.

From a financial perspective, SThree ended the year with a robust balance sheet, reporting net cash of £68 million. This strong liquidity position underpins the company’s intention to pursue an additional share buyback programme, highlighting management’s confidence in cash generation and capital discipline. While overall revenue and cash flow remain under pressure, financial stability has been maintained.

Looking ahead, SThree’s outlook is supported by attractive valuation metrics and positive corporate developments. Although trading conditions remain challenging, technical indicators point to bullish momentum, reinforcing a cautiously optimistic view on the company’s prospects as productivity improvements begin to take effect.

More about SThree plc

SThree plc is a global STEM workforce consultancy focused on science, technology, engineering, and mathematics markets. The company provides both contract and permanent recruitment solutions, with a strong international footprint, particularly in the United States, Germany, and the Netherlands.

U.S. stock index futures were trading higher ahead of Monday’s open, signaling a possible attempt by Wall Street to claw back some of the losses suffered during last week’s sharp sell-off.

Investors appear to be selectively buying after Friday’s pullback, which was driven primarily by heavy declines across the technology sector. That said, trading volumes could remain light as markets await several high-profile U.S. economic releases scheduled for the days ahead.

Attention will turn to Tuesday’s release of the November employment report and October retail sales figures, followed by November consumer inflation data due on Thursday. These reports could influence expectations around the Federal Reserve’s next policy steps after last week’s rate decision.

The Fed cut interest rates by 25 basis points as expected, but its latest projections highlighted growing divisions among policymakers over whether additional easing will be needed.

Stocks ended last week on a weak note after a mixed performance on Thursday gave way to broad selling pressure on Friday. All major indices finished lower, with the technology-heavy Nasdaq leading the declines.

By the closing bell, the Nasdaq had fallen 398.69 points, or 1.7%, to 23,195.17. The S&P 500 dropped 73.59 points, or 1.1%, to 6,827.41, while the Dow Jones Industrial Average slipped 245.96 points, or 0.5%, to 48,458.05, despite briefly touching a new intraday high earlier in the session.

Weekly results were mixed, with the Dow gaining 1.1% over the period, while the S&P 500 fell 0.6% and the Nasdaq declined 1.6%.

Technology stocks were at the center of Friday’s sell-off. Broadcom (AVGO) was among the hardest hit, plunging more than 11% despite posting stronger-than-expected quarterly earnings and issuing upbeat guidance.

Losses also extended to other major chip and software names, including Micron Technology (NASDAQ:MU), Oracle (NYSE:ORCL), Advanced Micro Devices (NASDAQ:AMD) and Nvidia (NASDAQ:NVDA), underscoring an ongoing rotation away from tech.

Market sentiment was further weighed down by comments from Chicago Fed President Austan Goolsbee, who explained his opposition to last week’s rate cut. In remarks published on the Chicago Fed’s website, Goolsbee said he was concerned about “moving too quickly on rate cuts and assuming inflation pressures will fade on their own.”

“I supported rate reductions at the September and October meetings, but I think we should have waited for more evidence — particularly on inflation — before cutting further,” he said.

Computer hardware stocks were among the weakest performers on Friday, dragging the NYSE Arca Computer Hardware Index down more than 5%. Semiconductor and networking shares also came under heavy pressure, contributing to the Nasdaq’s sharp decline.

Outside of technology, stocks in oil services, brokerage firms and steelmakers also fell, while pharmaceutical names showed relative resilience.

European equities traded mostly higher on Monday as investors positioned themselves for a packed week featuring important U.S. economic releases and a series of monetary policy decisions from major central banks.

Markets largely brushed aside fresh data from Germany showing an acceleration in wholesale price inflation in November to its fastest pace in nine months. Wholesale prices increased 1.5% year over year, up from a 1.1% rise in October and the strongest reading since February.

By late morning, Germany’s DAX was up around 0.3%, while gains were stronger elsewhere, with the UK’s FTSE 100 and France’s CAC 40 both advancing about 1.0%.

On the corporate front, shares in health technology group Royal Philips slipped after the company announced an agreement to acquire SpectraWAVE.

Sanofi (EU:SAN) also came under pressure after the French drugmaker said its experimental therapy tolebrutinib failed to achieve its primary endpoint in a Phase 3 study. The company added that a U.S. regulatory decision on the treatment for a form of multiple sclerosis is now likely to be delayed again.

Hikma Pharmaceuticals (LSE:HIK) shares declined as well, following news that Chief Executive Officer Riad Mishlawi has stepped down by mutual agreement.

Defense stocks were broadly weaker after Ukrainian President Volodymyr Zelenskyy indicated a willingness to abandon Ukraine’s bid to join NATO following discussions with the United States.

In contrast, Sika (TG:SIKA) shares moved higher after the specialty chemicals group said it plans to acquire Finja for an undisclosed sum.